AU Patent

AU2021216055A1 — Compositions and methods for treating pompe disease

Assigned to Genzyme Corp · Expires 2022-09-29 · 4y expired

What this patent protects

The present application provides methods of treating Pompe disease such as infantile- onset Pompe disease (IOPD) using a pharmaceutical composition comprising an oligosaccharide-acid a-glucosidase (GAA) conjugate, such as avalglucosidase alfa. Also provided are formulations of th…

USPTO Abstract

The present application provides methods of treating Pompe disease such as infantile- onset Pompe disease (IOPD) using a pharmaceutical composition comprising an oligosaccharide-acid a-glucosidase (GAA) conjugate, such as avalglucosidase alfa. Also provided are formulations of the oligosaccharide-GAA conjugates.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021216055A1
Jurisdiction
AU
Classification
—
Expires
2022-09-29
Drug substance claim
No
Drug product claim
No
Assignee
Genzyme Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.